Britain and America have announced a significant commercial pact that will ensure no duties on UK medicine exports going into the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to boost expenditure on medicines through the National Health Service (NHS). This move ensures that tariffs on these key exports will stay at zero for a timeframe of 36 months.
This development comes after recent warnings to hike duties on branded drug products, with potential rates discussed reaching 100%.
"This arrangement between the Britain reinforces the worldwide climate for innovative medicines and introduces much-needed equity to American-British medicine commerce," a release declared.
Trade Significance
Medicines are one of the UK's biggest goods shipped to the America, which is easily the primary buyer for large British pharmaceutical firms.
Trade data indicate that in the one-year period prior to September, the UK sold drugs valued at £11.1bn to the US. This value made up 17.4% of all goods exports in that period.
"This agreement protects employment, stimulates investment and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The deal entails several key pledges from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Previously, refunds were more than twenty percent.
Recent Tensions
The deal takes place against a ongoing row between the drug companies and the UK government over drug pricing and approval rates.
These tensions were exacerbated by claims that American patients were paying significantly more for the same drugs than people in the other developed nations.
Recently, several significant manufacturing plans in the UK have been delayed or abandoned, while major expansions have been directed toward projects in the United States.
One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a share of its total funding over the past decade.
